Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07065773 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
A Phase 2 study of Onychomycosis of Toenail, sponsored by Vanda Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT07065773: Active Phase 2 study of Onychomycosis of Toenail, sponsored by Vanda Pharmaceuticals.
NCT07065773 is a Phase 2 study of Onychomycosis of Toenail that is active but no longer recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07065773, a Phase 2 study of Onychomycosis of Toenail, is active but no longer recruiting, sponsored by Vanda Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.
Primary Outcome
Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.
Conditions Studied
Interventions
- DRUG Trichostatin A
Study Locations (5)
California
- Vanda Investigational Site - Fremont
Colorado
- Vanda Investigational Site - Denver
Minnesota
- Vanda Investigational Site - New Brighton
Texas
- Vanda Investigational Site - Pflugerville
Virginia
- Vanda Investigational Site - Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT07065773 still lists
NCT07065773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Onychomycosis of Toenail appearing as the primary indexed condition, and to 1 intervention - of which Trichostatin A is the first listed.
NCT07065773 lists 5 locations in 5 states (California, Colorado, Minnesota).
Frequently Asked Questions
What is clinical trial NCT07065773 about?
NCT07065773 is a clinical study titled "Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis". This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy ex...
What is the current status of trial NCT07065773?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-05. Estimated completion is 2026-09.
What conditions does trial NCT07065773 study?
This clinical trial studies the following conditions: Onychomycosis of Toenail.
What interventions are being tested in trial NCT07065773?
The interventions under investigation include: Trichostatin A (DRUG).
Who is sponsoring clinical trial NCT07065773?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07065773 being conducted?
This trial has 5 study locations across California, Colorado, Minnesota, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis of Toenail
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07065773's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI